parsaclisib,ruxolitinib
novartis,incyte
['parsaclisib', 'ruxolitinib', 'rux,(-crux),(-trux)', 'rux,(-crux),(-trux),(-deruxtecan)']
good morning #ash22, don t miss presenting efficacy and safety of add-on parsaclisib to ruxolitinib therapy in myelofibrosis patients with suboptimal response to ruxolitinib: final results from a phase 2 study in room 217-219 at 2:15 pm et. 
We are transforming cancer research and clinical care by linking our innovative approach to drug discovery, delivery and development to our patient care program